2025 SOA Health Meeting: Session 7A: Integrated Analytics for GLP-1 Therapy Management: Optimizing Clinical and Financial Value -06.24.25- Recording

With the rapid increase in utilization and the high costs associated with GLP-1 medications, healthcare payers are actively seeking effective management strategies for this drug class. As the demand for these medications continues to rise, driven by their proven benefits in treating diabetes, aiding weight loss, and managing chronic conditions, payers are confronted with complex decisions regarding coverage and cost management. Numerous questions remain unanswered, including those related to benefit coverage decisions, utilization management, care coordination, therapy costs, lifestyle management, medication adherence, and both short- and long-term clinical and financial outcomes.
This session aims to provide a comprehensive overview of these considerations, emphasizing the critical role of flexible analytics in evaluating the financial implications of GLP-1 drugs. These analytics are essential across chronic conditions for which these medications are approved or under study. The presentation will delve into initial findings from specific models and dashboards that enable continuous monitoring, offering payers actionable insights to refine care strategies and understand the impact of GLP-1s on Total Cost of Care (TCOC). We will examine initial findings regarding adherence levels and total medical expenses for chronic conditions. The importance of considering the net cost of GLP-1 medications, including potential rebates, when assessing total cost of care will also be discussed. Attendees will gain insights into strategic approaches using configurable dashboards to monitor emerging trends, evaluate TCOC impact, and optimize strategies amidst evolving evidence.